Operative mortality fell over time, but there was a concerning uptick in recent years attributed to low-volume sites.

There was a consensus that more data are needed to answer this question, with discussions about what such a trial would look ...

Outcomes and expenses were similar with transplant and elective LVAD, but urgent LVAD after ECMO fared much worse.

PE or PEERLESS, the choice of therapy was shifting, influenced by patient factors and institutional protocols.

The study emphasizes the importance of vigilance with diet and exercise, among other things, to reduce CV risk in type 2 diabetes.

Patients already had high NT-proBNP levels at baseline, though, raising questions about the quality of GDMT, Nancy Sweitzer ...

Even as BAT expands beyond trial criteria, patients see gains in LVEF, symptoms, and more. A survival impact remains unclear.

Mamas Mamas, Miguel Nobre Menezes, and Pietro Ameri discuss the special considerations when treating patients with cancer.

Doctors say that identifying the right patients will be critical to the future of the field. Only time will tell, according ...

The findings suggest clinicians don’t need to be as aggressive in lowering BP in this population, at least early after ...

Amid late-breaking coronary, structural, and endovascular trials will be a keynote from President Biden, and more.

It may seem overwhelming, but committee chair Karen Joynt Maddox says small changes may help turn things around.